Daily Ards Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
Evidence syntheses and real-world data refine ARDS-related care today: a meta-analysis of pediatric RCTs shows prone positioning reduces mortality, while a pediatric TBI meta-analysis quantifies safety signals (including a 4.5% ARDS rate) and rapid ICP lowering with hypertonic saline. A hospital cohort links barotrauma (pneumothorax/pneumomediastinum) in COVID-19 pneumonia to markedly higher mortality, even without mechanical ventilation.
Research Themes
- Pediatric ARDS management with prone positioning
- Safety–efficacy profile of hyperosmolar therapy in pediatric neurocritical care
- Barotrauma as a prognostic marker in COVID-19 pneumonia
Selected Articles
1. Prone positioning in pediatric acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials.
Across 13 pediatric RCTs (n=1,529), prone positioning reduced mortality versus supine ventilation (RR 0.67, 95% CI 0.57–0.79) and improved oxygenation, without clear reductions in ventilation duration or ICU stay. Findings support prone positioning as an adjunct in pediatric ARDS, pending further high-quality trials to optimize implementation.
Impact: Provides RCT-synthesized evidence specific to pediatric ARDS, addressing a long-standing gap by moving beyond adult extrapolation. The mortality signal is clinically meaningful and methodologically rigorous.
Clinical Implications: Consider early prone positioning in pediatric ARDS as an adjunct to lung-protective ventilation, with protocolized implementation and monitoring. Do not expect shorter ventilation or ICU stay solely from proning.
Key Findings
- Meta-analysis of 10 trials showed lower mortality with prone vs. supine ventilation (RR 0.67, 95% CI 0.57–0.79).
- Prone positioning improved oxygenation compared with supine ventilation.
- No clear reduction in mechanical ventilation duration or ICU length of stay with prone positioning.
Methodological Strengths
- Included 13 RCTs with a total of 1,529 pediatric patients.
- Cochrane risk-of-bias tool applied; multi-database search up to Oct 29, 2025.
- Quantitative synthesis performed in R with standard meta-analytic methods.
Limitations
- Heterogeneity in pediatric populations and proning protocols may affect effect estimates.
- No clear impact on ventilation duration or ICU stay; larger high-quality RCTs are needed to refine patient selection.
Future Directions: Conduct large, multicenter RCTs to identify subgroups most likely to benefit, define optimal timing/duration of proning, and integrate safety and implementation outcomes.
INTRODUCTION: Acute respiratory distress syndrome (ARDS) in children, characterized by acute lung inflammation and impaired gas exchange, presents unique therapeutic challenges due to developmental differences in respiratory physiology. While prone positioning is established in adult ARDS management, its efficacy in pediatric populations remains debated. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating prone vs. supine ventilation in children and adolescents (0-18 years) with ARDS. Databases including PubMed, MEDLINE, Embase, CINAHL and CENTRAL were searched up to October 29, 2025. Methodological quality was assessed using the Cochrane risk-of-bias tool, and statistical synthesis was performed in R. RESULTS: Thirteen RCTs (1,529 patients) were included. A meta-analysis of ten trials demonstrated a lower risk of death with prone compared with supine ventilation [risk ratio (RR) 0.67, 95% confidence interval (CI) 0.57-0.79; CONCLUSION: Prone positioning may reduce mortality and improve oxygenation in pediatric ARDS, but does not clearly shorten mechanical ventilation duration or ICU stay. These potential benefits support considering prone positioning as an adjunctive strategy in pediatric critical care protocols, while underscoring the need for larger, high-quality RCTs to refine patient selection and optimize implementation strategies.
2. Time-dependent efficacy and safety of hypertonic saline versus mannitol in pediatric traumatic brain injury: a systematic review and meta-analysis.
Across 14 pediatric TBI studies (n=680), hypertonic saline increased serum sodium and showed adverse-event rates including severe hypernatremia (37%), AKI (2.1%), and ARDS (4.5%), while mortality was similar to mannitol (RR 0.78; 95% CI 0.50–1.23). HTS rapidly and time-dependently lowered ICP (−17.35 mmHg at 30 min; −9.72 at 60 min; −8.45 at 24 h) without differences in CPP, ICU/hospital stay, or ventilation duration.
Impact: Clarifies the comparative safety–efficacy of hyperosmolar agents in pediatrics, quantifying ARDS incidence and time-resolved ICP reduction—critical for protocolized neurocritical care.
Clinical Implications: Either HTS or mannitol can be selected for ICP control in pediatric TBI with similar mortality; HTS offers rapid ICP reduction but requires vigilant monitoring for hypernatremia, AKI, and ARDS.
Key Findings
- HTS increased serum sodium (mean +5.47 mEq/L; 95% CI 1.30–9.64) and had severe hypernatremia in 37% (rising to 53% after resolving heterogeneity).
- Adverse events with HTS included AKI 2.1% and ARDS 4.5%.
- No significant mortality difference between HTS and mannitol (RR 0.78; 95% CI 0.50–1.23) and similar survival (RR 1.05; 95% CI 0.96–1.14).
- HTS produced time-dependent ICP reductions: −17.35 mmHg (30 min), −9.72 mmHg (60 min), −8.45 mmHg (24 h).
- No significant differences in CPP at 24 h, ICU/hospital length of stay, or mechanical ventilation duration.
Methodological Strengths
- Comprehensive multi-database search with predefined primary and secondary outcomes.
- Random-effects meta-analyses with 95% CIs; time-resolved ICP effects quantified.
- Includes comparative analysis versus mannitol with certainty statements.
Limitations
- Heterogeneity across included studies and dosing/administration protocols may limit precision.
- Mixed study designs and limited pediatric sample sizes; standardized protocols and long-term outcomes are lacking.
Future Directions: Conduct multicenter RCTs with standardized dosing and monitoring to compare HTS vs mannitol on long-term neurological outcomes and safety, including ARDS risk.
BACKGROUND: Traumatic brain injury (TBI) represents a significant cause of morbidity and mortality in children, with secondary injuries such as elevated intracranial pressure (ICP) significantly impacting outcomes. Hyperosmolar therapy is a cornerstone of acute management, with hypertonic saline (HTS) and mannitol as principal agents; however, comparative evidence regarding their efficacy and safety in pediatric populations remains inconclusive. METHODS: Comprehensive searches of PubMed, Embase, and CENTRAL were performed up to June 2025. Primary outcomes were ICP reduction and all-cause mortality; secondary outcomes included neurological outcomes, adverse events, ICU/hospital stay, and physiological parameters. Meta-analyses employed random-effects models to pool risk ratios (RR), mean differences (MD), and proportions with 95% confidence intervals (CI). RESULTS: A total of 14 studies, including 680 pediatric patients with TBI, were analyzed. HTS was associated with an increase in serum sodium (mean change 5.47 mEq/L; 95% CI: 1.30-9.64), severe hypernatremia (37%; on resolving heterogeneity rose to 53%), acute kidney injury (2.1%), and acute respiratory distress syndrome (4.5%). Comparative meta-analysis revealed no significant difference in mortality between HTS and mannitol (RR = 0.78; 95% CI: 0.50-1.23) and similar survival rates (RR = 1.05; 95% CI: 0.96-1.14), with high certainty. The pooled mortality rate for HTS was 17% (95% CI: 11%-24%), and survival was 83% (95% CI: 76%-89%). Pooled HTS analyses demonstrated a time-dependent decrease in ICP: 17.35 mmHg at 30 minutes, 9.72 mmHg at 60 minutes, and 8.45 mmHg at 24 hours. No significant differences were found for cerebral perfusion pressure (CPP) at 24 hours, ICU stay, hospital stay, or mechanical ventilation duration. CONCLUSION: In pediatric TBI, hypertonic saline and mannitol provide comparable efficacy for ICP reduction and mortality, with HTS demonstrating rapid ICP lowering and manageable safety signals. While HTS is generally well tolerated, further high-quality multicenter RCTs with standardized protocols and long-term outcomes are needed to clarify its clinical advantages over mannitol.
3. Prognostic Implications of Pneumothorax and Pneumomediastinum in COVID-19 Pneumonia: A Cross-Sectional Analysis.
In a tertiary-center cohort of 527 hospitalized COVID-19 pneumonia patients, 43 developed pneumothorax and/or pneumomediastinum; overall mortality was 28.3%, and mortality was markedly higher with these events (69.7%). Notably, 21% of events occurred on supplemental oxygen or HFNC, underscoring that barotrauma risk and prognostic significance extend beyond mechanically ventilated patients.
Impact: Quantifies the mortality impact of barotrauma in COVID-19 pneumonia and highlights risk in non-ventilated patients, informing surveillance and escalation strategies.
Clinical Implications: Maintain high suspicion for pneumothorax/pneumomediastinum in hypoxemic COVID-19 patients, including those on HFNC or supplemental oxygen, with prompt imaging and management; optimize ventilatory pressures to mitigate barotrauma.
Key Findings
- Among 527 hospitalized COVID-19 pneumonia patients, 43 had barotrauma events (18 PM, 10 PT, 15 both).
- Overall mortality was 28.3%; mortality was significantly higher with events (69.7%).
- Twenty-one percent of events occurred in patients on supplemental oxygen or HFNC (non-ventilated).
- Mortality appeared related to underlying disease severity rather than the events per se.
Methodological Strengths
- Includes both ventilated and non-ventilated patients, enhancing generalizability of barotrauma risk.
- Explicit event stratification (PT, PM, both) with in-hospital mortality comparison.
Limitations
- Single-center, retrospective cross-sectional design with potential confounding and selection bias.
- Incomplete reporting of ventilatory parameters and temporal relationships may limit causal inferences.
Future Directions: Prospective multicenter cohorts controlling for severity and ventilatory parameters to define causal pathways and thresholds for barotrauma risk in viral pneumonia.
INTRODUCTION: The prognostic implications of developing pneumothorax (PT) or pneumomediastinum (PM) in COVID-19 pneumonia remain a topic of debate, with current literature showing conflicting data. We aimed to assess mortality rates and the characteristics of patients with COVID-19 pneumonia who developed these complications compared to those who did not. METHODS: We analyzed data and outcomes for patients aged 18 years or older who were admitted for COVID-19 pneumonia to a tertiary care referral center in Lebanon. RESULTS: A total of 527 patients (356 men and 171 women) were identified. Events were reported in 43 patients (18 PM, 10 PT, and 15 both). Overall mortality was 28.3%. Mortality was significantly higher in patients with events compared to those without events (69.7% DISCUSSION: Barotrauma events, including PT and PM in COVID-19 pneumonia, were associated with significantly higher mortality and appear to reflect more severe lung involvement. Mortality was not directly caused by the events themselves. A significant proportion occurred in patients on supplemental oxygen or high-flow nasal cannula (21%), highlighting the need for a high index of suspicion for such events even in non-ventilated patients. CONCLUSION: There is a strong association between the development of PT and/or PM and mortality in COVID-19 pneumonia.